Oct 17, 2017
Hologic Receives CE Mark to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin)
Hologic, Inc. (Nasdaq: HOLX) announced today that it has received an additional European Medical Device Directive (MDD) certification for SculpSure®, a state-of-the-art body contouring laser...
Oct 11, 2017
The common condition costing £531m a year in lost work days
--73% of women with heavy periods lie about the reason for taking days off, suggesting this common condition, which affects 1 in 5 women,2 is still a taboo --
London, UK October 11, 2017 - New survey results released today highlight the considerable impact and lack of awareness of heavy periods, which affect one in five women. That’s over 4 million...
Oct 5, 2017
Panther Fusion® Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion® System
- New Panther Fusion Module Expands System's Molecular Testing Capabilities, Increases Efficiency and Flexibility for the Laboratory
Hologic, Inc. (Nasdaq: HOLX) announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Panther Fusion® Flu A/B/RSV assay running on...
Oct 4, 2017
Hologic Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 4.375% Senior Notes Due 2025
Hologic, Inc. (NASDAQ: HOLX) announced today that it has priced its previously announced private offering of $350 million aggregate principal amount of 4.375% senior notes due 2025 at an issue...
Oct 4, 2017
New Study Shows Increased Fetal Fibronectin (fFN) Testing in Pregnant Women Could Help Guide Better Patient Care
-- Increased fFN testing could improve care management by preventing more women with symptoms of preterm labor from being discharged from the hospital too soon --
MARLBOROUGH, Mass., October 4, 2017 – A new study found that women with symptoms of preterm labor who were discharged from the hospital without a fetal fibronectin (fFN) test were more likely to...